Related Experiment Videos
[Legal and economic aspects of peritoneal dialysis]
1l'AURA, Paris.
Insights
Current reimbursement for peritoneal dialysis (PD) in France is inadequate for newer techniques like continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). Despite long-term cost savings and improved patient quality of life, insufficient funding hinders the development of these renal insufficiency treatments.
Area of Science:
- Nephrology
- Public Health Policy
- Healthcare Economics
Background:
- Renal insufficiency treatment in France is primarily governed by hospital law, with specific regulations for hemodialysis centers.
- Continuous Ambulatory Peritoneal Dialysis (CAPD) is currently regulated by a 1979 memorandum with a fixed weekly price, not encompassing newer methods.
- Existing reimbursement structures do not account for the higher costs associated with advanced PD techniques.
Purpose of the Study:
- To analyze the cost-effectiveness of newer peritoneal dialysis (PD) techniques compared to existing reimbursement frameworks.
- To highlight the financial implications of inadequate reimbursement for advanced PD methods.
- To advocate for policy adjustments to support the development and adoption of PD treatments for renal insufficiency.
Main Methods:
- Cost analysis based on a 1992 survey by AURA (Paris) examining the first six months of 1992.
- Comparison of additional costs for double-bag CAPD and Automated Peritoneal Dialysis (APD) against current fixed prices.
- Evaluation of long-term economic benefits of PD, including reduced peritonitis risk and enhanced patient socio-professional activity.
Main Results:
- Newer PD techniques, such as double-bag CAPD and APD, incur significant additional costs (45% and 80% respectively) above the current fixed weekly price.
- These advanced PD methods offer potential long-term savings for national health insurance by mitigating complications and improving patient independence.
- Current reimbursement deficits due to inadequate pricing are stifling the growth and implementation of these beneficial renal replacement therapies.
Conclusions:
- The current reimbursement policy for peritoneal dialysis in France is insufficient to cover the costs of advanced techniques like CAPD and APD.
- Despite higher initial costs, PD offers long-term economic advantages and improved patient outcomes compared to hemodialysis.
- Urgent reconsideration by Public Service Authorities is needed to align reimbursement with the true costs and benefits of modern PD therapies for renal insufficiency management.
Abstract:
Treatment of renal insufficiency is, in it principle, covered by "hospital law" and its decrees of application: however the regulations for these methods of treatment only concern hemodialysis centers. CAPD is only subjected to a memorandum from the "Caisse Nationale d'Assurance Maladie" (National Medical Insurance) dated November 26, 1979, which fixes a weekly price. The text only concerns CAPD with single bag and does not deal the new methods. These new techniques are very expensive and well above the current weekly fixed price. According to a survey of the cost, carried out by AURA (Paris), during the first six months in 1992, the price of such techniques involves an average additional cost of 45% when double bags were used and 80% when APD was operated. In the long term, these techniques will result in substantial savings for the National Medical insurance scheme by reducing the risk of peritonitis and by facilitating patients' social and professional activity. However, the absence of adequate reimbursement causes running deficits and curbs development. Public Service Authorities should consider all these factors and should not forget that PD is generally cheaper than hemodialysis.